Anavex to Present at Alzheimer’s Association International Conference on Alzheimer’s Disease

Hoboken, NJ — July 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzheimer’s Association International Conference on Alzheimer’s Disease (AAICAD) in…

Anavex Raises $1.575 million

Hoboken, NJ — July 11, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to announce that it has raised $1,575,000 through the exercise of warrants.  Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease, to advance other compounds in…

Anavex First-in-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease

Hoboken, NJ — April 20, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease. “We are pleased that the first volunteers have been dosed with the…

Anavex Appoints Dr. Christopher Shackleton as an Advisor

Hoboken, NJ — April 8, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the appointment of Dr. Christopher Shackleton as an advisor to the Company. Dr. Shackleton is a prominent, uniquely qualified physician and surgeon, clinical investigator, information technologist, and corporate finance/healthcare solutions consultant.  He holds triple specialist credentials in medical and…